In:
The Journal of Immunology, The American Association of Immunologists, Vol. 202, No. 1_Supplement ( 2019-05-01), p. 194.22-194.22
Abstract:
Cancer patients generate tumor-specific B lymphocytes which can be isolated to develop human mAbs against tumor-associated antigens. Pritumumab (also referred to as CLNH-11, CLN-IgG, or ACA-11) is a classic example of a natural human anti-cancer antibody. It is a natural human IgG1 kappa antibody developed by human hybridoma technology, using B lymphocytes isolated from a regional draining lymph node of a patient with cervical carcinoma. Phase II clinical trials with pritumumab have demonstrated an objective response as a therapeutic antibody for glioblastoma. Here we demonstrate pritumumab binds cell surface expressed vimentin, also referred to as ecto-domain vimentin (EDV). Vimentin is an intracellular cytoskeletal protein overexpressed during epithelial-to-mesenchymal transition (EMT), a process integral to cancer cell metastasis. The potential of pritumumab as a therapeutic antibody targeting glioblastoma was evaluated. We demonstrate pritumumab binding to patient glioblastoma cells and antibody binding to these cells induces antibody-dependent cell-mediated cytoxicity (ADCC). Furthermore, pritumumab effectively inhibited glioma tumor growth in a xenograft mouse model. Overall, these data provide pre-clinical validation of pritumumab mAb as a therapeutic for glioblastoma.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.202.Supp.194.22
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2019
detail.hit.zdb_id:
1475085-5
Permalink
